undamentalytics Newsletter
Sign in

Arcus Biosciences, Inc. balance sheet

At the end of fiscal 2025, Arcus Biosciences, Inc. had total assets of $1.14bn and shareholders' equity of $631m. It held $222m in cash against $100m of debt: net cash of $122m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents987158173148206127150222150
Total current assets1772591937361,2621,0678311,0161,007756
Total assets1902752037721,5921,3451,0951,1501,139924
Accounts payable43516102017184234
Deferred revenue (current)567751029791853519
Total current liabilities131723122166193184226231198
Long-term debt——————04899101
Total debt000000050100101
Total liabilities374039270750—————
Shareholders' equity−72235164502842657462485631464
Non-controlling interests and other (assets − liabilities − equity)226—————————
Net debt (negative = net cash)−98−71−58−173−148−206−127−100−122−49
Shares outstanding——46m65m71m73m76m92m125m127m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: RCUS vs SPRYMESO vs RCUSRCUS vs XNCRAGEN vs RCUS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arcus Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcus Biosciences, Inc.